Vera Therapeutics (VERA) Notes Payables (2021 - 2026)

Vera Therapeutics has reported Notes Payables for 6 years, with the latest figure at $75.0 million in Q1 2026.

• For the quarter ending Q1 2026, Notes Payables rose 50.0% year-over-year to $75.0 million; the trailing twelve-month figure through Mar 2026 stood at $75.0 million (up 50.0% YoY), and the FY2025 full-year result was $75.0 million, up 50.0% from the prior year.
• Notes Payables for Q1 2026 stood at $75.0 million, roughly flat from $75.0 million in the prior quarter.
• The five-year high for Notes Payables was $75.0 million in Q2 2025, with the low at $25.0 million in Q4 2022.
• Historically, Notes Payables has averaged $50.0 million across 5 years, with a median of $50.0 million in 2023.
• Annual changes were most pronounced in 2022 — Notes Payables soared 400.0% — and 2024, when it changed 0.0%.
• Vera Therapeutics' Notes Payables stood at $25.0 million in 2022, then surged by 100.0% to $50.0 million in 2023, then changed by 0.0% to $50.0 million in 2024, then jumped by 50.0% to $75.0 million in 2025, then changed by 0.0% to $75.0 million in 2026.
• The last three Notes Payables figures came in at $75.0 million (Q1 2026), $75.0 million (Q4 2025), and $75.0 million (Q3 2025), per Business Quant data.